19-nor-vitamin d analogs with 1,2,or 3,2 heterocyclic ring

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 311/74 (2006.01) A61K 31/352 (2006.01) A61P 3/04 (2006.01)

Patent

CA 2647981

19-nor-vitamin D analogs having an additional heterocyclic ring connecting the 3.beta.-oxygen and carbon-2 or the 1.alpha.-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit significant activity in mobilization of bone, making them therapeutic agents for the treatment or prophylaxis of osteoporosis, osteomalacia, osteopenia, renal osteodystrophy and hypoparathyroidism.

L'invention concerne des analogues de la 19-nor-vitamine D, qui présentent un noyau hétérocyclique supplémentaire reliant le 3.beta.-oxygène et le carbone-2 ou le l.alpha.-oxygène et le carbone-2 du noyau A de l'analogue; et leurs utilisations pharmaceutiques. Ces composés présentent une activité considérable de mobilisation de l'os, ce qui en fait des agents thérapeutiques destinés au traitement ou à la prophylaxie de l'ostéoporose, l'ostéomalacie, l'ostéopénie, l'ostéodystrophie rénale et l'hypoparathyroïdie.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

19-nor-vitamin d analogs with 1,2,or 3,2 heterocyclic ring does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 19-nor-vitamin d analogs with 1,2,or 3,2 heterocyclic ring, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 19-nor-vitamin d analogs with 1,2,or 3,2 heterocyclic ring will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1436927

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.